重组人白细胞介素-11联合多西紫杉醇、卡铂治疗晚期非小细胞肺癌的效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (580 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 80 patients with advanced NSCLC admitted to Maanshan People′s Hospital, Anhui Province from December 2015 to June 2019 were selected and divided into the control group and the treatment group according to the random number table method, with 40 cases in each group. The control group were treated with Docetaxel and Carboplatin, while the treatment group were treated with Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin for 21 days as one chemotherapy cycle, and both groups were treated for 3 consecutive chemotherapy cycles. The clinical effect of two groups after treatment was evaluated and compared. Eastern cooperative oncology group (ECOG) scores, cytokeratin-19-fragment (CYFRA21-1), insulin-like growth factors-1 (IGF-1), squamous cell carcinoma antigen (SCC-Ag) and peripheral blood CD3+, CD4+, and CD8+ levels were compared between the two groups before and after treatment. The occurrence of toxic side effects during treatment was compared between the two groups. Results The total remission rate in the treatment group was significantly higher than that in the control group, with statistically significant difference (P ＜ 0.05). After treatment, ECOG scores of both groups were lower than those before treatment, and the treatment group was lower than the control group, with statistically significant differences (all P ＜ 0.05). After treatment, serum CYFRA21-1, IGF-1 and SCC-Ag levels in the two groups were all lower than those before treatment, and the treatment group was lower than the control group, with statistically significant differences (all P ＜ 0.05). After treatment, the levels of CD3+ and CD4+ in the control group were lower than those before treatment, and the levels of CD8+ were higher than those before treatment. The levels of CD3+ and CD4+ in the treatment group were higher than those before treatment, and the levels of CD8+ were lower than those before treatment. The levels of CD3+ and CD4+ in the treatment group were higher than those in the control group, and the levels of CD8+ were lower than those in the control group, with statistically significant differences (all P ＜ 0.05). During the treatment, the incidence of toxic side effects in the treatment group was lower than that in the control group, and the difference was statistically significant (P ＜ 0.05). Conclusion Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin has a significant clinical effect in the treatment of advanced NSCLC, which can improve the physical strength and quality of life of patients, down-regulate the serum CYFRA21-1, IGF-1 and SCC-Ag levels, and improve the immune function of the body.

Key words： Advanced non-small cell lung cancer Recombinant Human Interleukin-11 Docetaxel Carboplatin Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Eryun CUI Fangbo LI Min

Cite this article:

GAO Eryun CUI Fangbo LI Min. Effect of Recombinant Human Interleukin-11 combined with Docetaxel and Carboplatin in the treatment of advanced non-small cell lung cancer[J]. 中国医药导报, 2020, 17(20): 118-122.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I20/118

[1] 何燕，岳丽梅，夏劲节，等.2016-2018年成都市恶性肿瘤发病率分析[J].预防医学情报杂志，2019，35（11）：1268-1274.
[2] 李华伟，黄学武.青年肺癌与老年肺癌的研究现状[J].医学信息，2019，32（19）：54-57.
[3] 李亚莉，周恒根，倪敬忠，等.消癌平注射液联合TC方案治疗晚期非小细胞肺癌临床观察[J].现代中西医结合杂志，2015，24（3）：316-318.
[4] 孙玮，姚艳粉，李丕宝.奥沙利铂联合胸腔内灌注重组人白细胞介素-2治疗肺癌恶性胸水的疗效观察[J].中国肿瘤临床与康复，2019，26（6）：664-666.
[5] 中华医学会.临床诊疗指南肿瘤分册[M].北京：人民卫生出版社，2005.
[6] 支修益，石远凯，于金明.中国原发性肺癌诊疗规范（2015年版）[J].中华肿瘤杂志，2015，37（1）：67-78.
[7] 付娟，陈振东，魏芬芬，等.吉非替尼治疗不同ECOG体能状况评分的非小细胞肺癌的临床研究[J].肿瘤，2013， 33（4）：339-344.
[8] 徐心瑶，花宝金.老年非小细胞肺癌的现代医学研究进展[J].现代肿瘤医学，2017，25（23）：3900-3905.
[9] 马丹丹，刘坤，齐晓伟.2018年全球癌症统计：乳腺癌发病和死亡人数统计[J].中华乳腺病杂志：电子版，2018， 12（6）：375.
[10] 王华辉.晚期非小细胞肺癌患者预后的危险因素分析[J].临床合理用药杂志，2018，11（30）：130-132.
[11] 钟锐，邬麟，王伟，等.含铂化疗及其联合治疗在晚期非小细胞肺癌治疗中的研究进展[J].肿瘤药学，2019，9（6）：839-844.
[12] 林建芳，黄传钱，倪晓晓，等.卡铂对比顺铂联合第三代化疗药物治疗晚期非小细胞肺癌的Meta分析更新[J].肿瘤预防与治疗，2019，32（10）：880-888.
[13] 张明晖.培美曲塞联合卡铂治疗66例非小细胞肺癌的效果观察[J].实用癌症杂志，2015，30（11）：1649-1651， 1662.
[14] 孔德琦，刘苓霜，姜怡，等.中医药干预Ⅲa期非小细胞肺癌根治术后无病生存期及预后相关因素分析[J].国际中医中药杂志，2019，41（3）：8-13.
[15] 花小梅，彭辉，王江涛，等.多西紫杉醇在晚期非小细胞肺癌化疗中的应用效果[J].中国当代医药，2019，26（23）：53-55.
[16] 王斌，刘先领，王志东，等.卡铂联合多西紫杉醇治疗晚期非小细胞肺癌患者疗效观察[J].中外医学研究，2015（3）：26-27.
[17] 彭娜，康马飞，何少忠，等.重组人白细胞介素11对非小细胞肺癌患者转移和生存的影响[J].中国现代医生，2017，55（11）：50-52.
[18] 雷廷.白蛋白结合型紫杉醇治疗晚期恶性肿瘤的效果分析[J].国际医药卫生导报，2016，22（8）：1127-1129.
[19] 李素彦，王飞.血清CEA、CYFRA21-1、NSE、SCCA、PROGRP联合检测诊断肺癌的临床意义[J].现代医药卫生，2019，35（22）：3455-3457，3461.
[20] 张栓宝，姚俊涛.吉西他滨与顺铂联合化疗对晚期非小细胞肺癌患者CYFRA21-1、IGF-1及VEGF的影响[J].川北医学院学报，2017，32（2）：160-162，196.
[21] 刘涓，孙威.IL-6和IGF-1在非小细胞肺癌组织的表达与临床意义[J].中国组织化学与细胞化学杂志，2015， 24（5）：399-403.
[22] 苏航就.SCC-Ag CEA CYFRA21-1 D-二聚体联合检测对非小细胞肺癌的早期诊断价值[J].基层医学论坛，2019，23（29）：4223-4224.
[23] 于淼.肺癌患者焦虑程度与术后营养状况及免疫功能的关系研究[J].中国医学创新，2019，16（36）：128-131.
[24] 陈秀艳，华燕艳，李杰，等.紫杉醇联合顺铂化疗和低分子肝素钠治疗老年非小细胞肺癌患者的效果[J].中国医药，2018，13（11）：1651-1654.
[25] 常旭，赵微，张成桂，等.T细胞亚群在肿瘤微环境中的作用[J].国际免疫学杂志，2016，39（1）：53-56.
[26] 卢央芳，陆意，仇建波，等.紫杉醇、卡铂联合重组人白细胞介素-11治疗晚期非小细胞肺癌的疗效及安全性分析[J].中国医师杂志，2019，21（9）：1400-1402.